Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCNU + Doxorubicin
- Development stage
- Unknown
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
CCNU + doxorubicin is a combination chemotherapy protocol used primarily in veterinary medicine, especially for treating canine histiocytic sarcoma and certain types of lymphoma. This protocol involves alternating administration of lomustine (CCNU) and doxorubicin, typically every 2 weeks. The protocol works by attacking cancer cells through different mechanisms simultaneously, potentially increasing efficacy compared to single-agent treatments. The combination consists of two distinct chemotherapy agents: Lomustine (CCNU), an alkylating agent, administered orally; and Doxorubicin, a commonly used chemotherapy drug, administered intravenously.
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on CCNU + Doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCNU + Doxorubicin.